Drug profile

The FDA adverse-event record for Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

147 FDA reports name Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#637 of 2,679
by report volume (all drugs)
147
adverse-event reports
10.9%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract ranks #635 of 2679 by total reports (147) and #507 of 1130 by death-coded share (10.9%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#635
This drug, reports of 2679
#507
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract has 147 reports now versus 147 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract changes

Signature read: 147 reports place Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract in the upper third of FDA AER volume (#637 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
147
Total Reports
16
Deaths Reported
10.9%
Death-coded share of reports

Active Ingredients

Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

Administration Routes

SubcutaneousUnknownParenteral

Species Affected

Dog 147

Most Affected Breeds

Retriever - Labrador 12
Shepherd Dog - Australian 11
Retriever - Golden 8
Siberian Husky 7
Crossbred Canine/dog 7
Shih Tzu 5
Terrier - Jack Russell 5
Terrier - Yorkshire 4
Spitz - German Pomeranian 4
Shepherd Dog - German 4

Most Reported Reactions

Vomiting 42
Lethargy (see also Central nervous system depression in 'Neurological') 24
Other abnormal test result NOS 19
Diarrhoea 18
Not eating 14
Anaphylaxis 11
Anorexia 10
Pale mucous membrane 10
Lethargy (see also Central nervous system depression in Neurological) 10
Death by euthanasia 9
Injection site swelling 9
Hives (see also 'Skin') 9

Outcome Breakdown

Recovered/Normal
57 (38.8%)
Outcome Unknown
43 (29.3%)
Ongoing
31 (21.1%)
Euthanized
9 (6.1%)
Died
7 (4.8%)

Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (10.9% here), distinct from the volume row.

Silver Sulfadiazine 10.9% Methylprednisone Acetate 10.8% Fenbendazole 10.9% Lyme 10.9%

What to do with this drug

  • Compare Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (#637 of 2,679 by report volume); death-coded 10.9%. PlainBreed drug row · report volume stamp 147 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →